Abstract

REPOSITIONING OF NON-STEROIDAL ANTI- INFLAMMATORY DRUGS FOR TARGETING NON-SMALL CELL LUNG CANCER BY MOLECULAR DOCKING STUDIES

Sharanabasav Biradar*, Prasad V. Malagi, Sammed P. Melavanki, Sushma Kagawade, Sneha Pattar, Aparna Pagi and Deepa Babaleshwar

ABSTRACT

Drug Repositioning/repourposining, as a smart way to exploit new molecular targets of a known drug, has been gaining increasing in the discovery of NSAIDS as anti- inflammatory & chemosensitive agents. NSAID’s as Diaryl-substituted Pyrazoles/ Furanones derivatives, which is essentially Selective COX-2 inhibitors. In recent years, exploiting the new application of NSAIDs in anticancer field has become a hot research topic. Therefore, it is of interest to reprofiling drugs against Non-Small Cell Lung Cancer target using molecular docking analysis. Results showed that known drugs such as Celecoxib, Etoricoxib, Valdecoxib, Rofecoxib, 5-Flurouracil has high binding affinity with mobile receptors for consideration as potential inhibitors.

Keywords: NSAIDS, Drug Repositioning, Molecular Docking.